Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

@article{Arroz2016ConsensusGO,
  title={Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.},
  author={Maria Jorge Arroz and Neil A Came and Pei Lin and Weina Chen and Constance M. Yuan and Anand S. Lagoo and Mariela Monreal and Ruth M de Tute and Jo-Anne Vergilio and Andy C Rawstron and Bruno Paiva},
  journal={Cytometry. Part B, Clinical cytometry},
  year={2016},
  volume={90 1},
  pages={31-9}
}
BACKGROUND Major heterogeneity between laboratories in flow cytometry (FC) minimal residual disease (MRD) testing in multiple myeloma (MM) must be overcome. Cytometry societies such as the International Clinical Cytometry Society and the European Society for Clinical Cell Analysis recognize a strong need to establish minimally acceptable requirements and recommendations to perform such complex testing. METHODS A group of 11 flow cytometrists currently performing FC testing in MM using… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…